Pubblicazioni

Autori:

Ferrero, S.; Gentile, Massimo; Laurenti, Luca; Romana Mauro, Francesca; Martelli, Maurizio; Sportoletti, Paolo; Visco, Carlo; Luigi Zinzani, Pier; Tedeschi, Alessandra; Varettoni, M.

Titolo:

Use of {BTK} inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement

Anno:

2022

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

Hematological Oncology

ISSN Rivista:

0278-0232

Intervallo pagine:

1382-1386

Parole chiave:

BTK inhibitors; Waldenström macroglobulinemia; ibrutinib; real-world; recommendations

Breve descrizione dei contenuti:

: The pivotal role that ibrutinib plays in the management of Waldenström macroglobulinemia (WM) is undisputed but there are ongoing questions regarding its positioning in the therapeutic algorithm of WM as well as in some peculiar clinical situations. A panel of experts from Italy was convened to provide real world recommendations on the use of BTK inhibitors in lymphoproliferative diseases in general, and in patients with WM in particular. This position paper represents the panel's collective analysis, evaluation, and opinions and is made up of a series of questions frequently asked by practicing clinicians and answers based on currently available evidence.

Id prodotto:

126846

Handle IRIS:

11562/1064969

ultima modifica:

20 dicembre 2024

Citazione bibliografica:

Ferrero, S.; Gentile, Massimo; Laurenti, Luca; Romana Mauro, Francesca; Martelli, Maurizio; Sportoletti, Paolo; Visco, Carlo; Luigi Zinzani, Pier; Tedeschi, Alessandra; Varettoni, M., Use of {BTK} inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement «Hematological Oncology» , 2022 , pp. 1382-1386

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo